凉血化瘀方治疗中心性渗出性脉络膜视网膜病变临床观察及实验研究
|
摘要
目的
通过临床病例,观察中药凉血化瘀方治疗中心性渗出性脉络膜视网膜病变(centralexudative chorioretinophy,CEC)的疗效。进一步通过动物实验,观察凉血化瘀中药对脉络膜新生血管(choroidal neovascularization,CNV)的影响,并初步探讨其作用机理,为中药凉血化瘀方用于临床治疗CEC提供依据。
方法
一、临床病例观察:
对70例70眼确诊的中心性渗出性脉络膜视网膜病变患者服凉血化瘀方中药治疗,将70眼分为中药组46眼,联合组15眼,陈旧组9眼。服中药3个月,总观察时间9个月。观察比较治疗前后最佳矫正视力(best corrected vision acuity,BCVA)、荧光眼底血管造影(fundus fluorescein angiography,FFA)和光学相干断层扫描(Optic coherenttomography,OCT)图像。
二、动物实验研究:
1.建立CNV动物模型,并评价可行性。
棕色挪威(brown Norway,BN)大鼠32只一眼行氪激光(659nm)眼底光凝,另一眼作空白对照。激光功率、光凝斑直径和曝光时间分别为360mW、50μm及0.05s。光凝20点。分别在光凝后7,14,21,28d随机选取7只大鼠行眼底照像、FFA检查。随机选取1只大鼠行脉络膜血管铺片检查。眼球标本行组织病理切片光镜、Ⅷ免疫组织化学染色观察。
2.评价不同浓度凉血化瘀中药对氪激光诱导BN大鼠CNV形态的影响,从中筛选最佳浓度。
659nm激光诱导BN大鼠CNV模型同1,随机分成空白对照组、高浓度、中浓度和低浓度中药组4组,每组6只,每日不同浓度中药灌胃。四组分别在光凝后7、14、21d随机选取2只大鼠行眼底照像、FFA检查。眼球标本行组织病理切片光镜、Ⅷ免疫组织化学染色观察。
3.比较中浓度凉血化瘀中药与曲胺耐德(triamcinolone acetonide,TA)对氪激光诱导BN大鼠CNV形态的影响。
659nm激光诱导BN大鼠CNV模型同1,随机分成空白对照组(16只),中药组(16只),曲胺耐德组(16只)。空白对照组每日生理盐水灌胃,中药组每日中药灌胃,曲胺耐德组术后第2d玻璃体腔内注射5μL(0.2mg)曲胺耐德。在光凝后7,14,21,28d每组随机选取3只大鼠行荧光素眼底血管造影(FFA)检查,检查后处死,取眼球行HE染色,Ⅷ因子相关抗原免疫组织化学检测;同时,每组选取1只大鼠做脉络膜血管铺片检查。
4.评价凉血化瘀中药及TA对氪激光诱导BN大鼠CNV中基质金属蛋白酶-9(Matrixmetalloproteinase 9,MMP-9)和基质金属蛋白酶抑制剂(tissue inhibitor ofmetalloproteinase 2,TIMP-2)表达的影响。
659nm激光诱导BN大鼠CNV模型同1,随机分成空白对照组,中药组和TA组各12只。分别在光凝后7,14,21,28d随机选取3只大鼠处死,摘除眼球,行病理切片及免疫组织化学检测MMP-9及TIMP-2蛋白在CNV组织中的表达。
结果
一、临床病例观察:
末次随访时,中药组46眼中,视力平均提高0.21,较治疗前有统计意义;视力≥4.7者33眼(71.7%);视力提高≥2行的25眼(54.3%),视力波动在1行以内者16只眼(34.8%),视力下降≥2行的5眼(10.9%),较治疗前视力明显提高。病灶直径、病灶面积,中央视网膜厚度与治疗前相比无统计学意义上的改变,黄斑容积较治疗前降低。FFA检查发现:显效(CNV闭合)34眼(73.9%),有效(CNV部分闭合)7眼(15.2%),进步(CNV小部分闭合)4眼(8.7%),无效(CNV扩大)0眼,较治疗前显著改善。OCT检查发现:CNV型别由治疗前活动期38眼(82.6%)、中间期8眼(17.4%),转变为有效(瘢痕期)38眼(82.6%),进步(中间期)6眼(13.1%),无效(活动期)2眼(4.4%),具有统计学意义。
联合组15眼中,视力平均提高0.12,视力分布及视力提高的情况较治疗前无明显改善,病灶直径、病灶面积、中央视网膜厚度及黄斑容积与治疗前相比均无统计学意义上的变化。FFA检查发现:显效(CNV闭合)13眼(86.7%),有效(CNV部分闭合)1眼(6.7%),无效(CNV扩大)1眼(6.7%),较治疗前显著改善。OCT检查发现:CNV型别由治疗前活动期7眼(46.7%)、中间期4眼(26.7%)、瘢痕期4眼(26.7%)均可出现,转变为有效(瘢痕期)13眼(86.7%),进步(中间期)1眼(6.7%),无效(活动期)1眼(6.7%),具有统计学意义。
陈旧组9眼,治疗后,病人主诉视疲劳的症状减轻,视力平均提高0.11,视力提高≥2行者3眼(33.3%),但是,与治疗前相比无统计学差异。病灶情况与治疗前相比无统计学差异。
二、动物实验研究:
1.659nm激光(360mW,50μm,0.05s)照射BN大鼠视网膜20点后,7～21d显示FFA晚期荧光素渗漏及光镜下CNV厚度逐渐增加,28d时FFA渗漏和CNV厚度开始减少。
2.FFA显示:光凝后7～21d,空白对照组CNV渗漏面积逐渐增大,而中药组渗漏面积增加无明显差异;至21d,中、低浓度中药组渗漏面积明显低于空白对照组和高浓度中药组,以中浓度中药组CNV渗漏面积最小。CNV厚度变化:空白对照组7～2ld逐渐增厚,至21d达到高峰;而中药组至14d CNV厚度达到高峰,14～21d CNV厚度变薄,以中浓度中药组CNV厚度最薄。
3.FFA显示:光凝后7～28d,空白对照组CNV渗漏面积逐渐增大,而中药组渗漏面积略增加,TA组瘢痕着色明显。CNV厚度:空白对照组逐渐增加,至21d达高峰,28d略有下降;中药组CNV厚度逐渐增加,至14d达到高峰,21d时明显变薄,28d再次增加;TA组7～14d时CNV逐渐变薄,至14d时最薄,此后CNV再次增厚。Ⅷ因子相关抗原阳性反应物吸光度:空白对照组7～14d时逐渐增加,至14d达到高峰,此后下降;中药组7d时达到高峰,此后下降;TA组亦是14d达到高峰,但峰值较空白对照组低,此后下降。脉络膜血管铺片CNV面积:空白对照组7～28d逐渐增大;中药组7～14d达到高峰,14～21d下降,28d时再次增加;TA组7～14dCNV面积逐渐增加,21,28d时瘢痕明显。
4.空白对照组在光凝后7d MMP-9达到高峰,此后逐渐下降;中药组在光凝后14d达到高峰,但峰值低于空白对照组,此后逐渐下降;曲胺奈德组在光凝后7d达到高峰,峰值介于空白对照组和中药组之间,此后逐渐下降,在14～21d出现平台期。空白对照组在光凝后14d TIMP-2达到高峰,此后逐渐下降;中药组在光凝后14d达到高峰,峰值高于空白对照组,此后逐渐下降;曲胺奈德组在光凝后14d达到高峰,峰值介于空白对照组和中药组之间,此后下降。
结论
一、临床病例观察:
中药凉血化瘀方可以促进CEC中CNV闭合,可以促进经过西医治疗后仍有CNV渗漏的CEC患者CNV闭合,可能改善陈旧CEC患者的视疲劳症状。
二、动物实验研究:
1.氪激光诱导BN大鼠的CNV模型是一种较为理想的模型,FFA及CNV厚度分析是CNV定量研究的有效手段。
2.中浓度凉血化瘀中药可以有效抑制氪激光诱导BN大鼠的CNV增生,防止CNV渗漏。
3.TA玻璃体腔注射可以明显抑制CNV形成,但后期形成瘢痕明显;凉血化瘀中药灌胃不仅有效抑制CNV增生,而且瘢痕较小。
4.在下调MMP-9,上调TIMP-2的表达进而抑制CNV形成方面,凉血化瘀中药的作用强于TA。
OBJECTIVE
To investigate the therapeutic effect of Chinese medicine of LiangXueHuaYu on central exudative chorioretinopathy(CEC).And to evaluate the changes of choroidal neovasculation (CNV) taking Chinese medicine of LiangXueHuaYu,investigate the possibility of LiangXueHuaYu decoction as a therapeutic agent for experimental CNV induced by Krypton laser in Brown Norway rats,and further to study their mechanism.Through the clinical cases and animal experiment,we hope we can provide the basis for LiangXueHuaYu decoction used in clinic to curing CEC.
METHODS
Clinical cases observation:
The clinical data of 70 patients(70 eyes) with CEC who had followed up for 9 months after therapy of Chinese medicine for CNV were analyzed.The cases were divided into three groups:Chinese medicine group(46 eyes),combined treatment group(15 eyes) and the scar group(9 eyes).The changes of the best corrected visual acuity(BCVA),Fundus Fluorescein Angiography(FFA) and Optic coherent tomography(OCT) were observed and analyzed.
Animal experiment study:
1.To investigate the feasibility of Krypton laser-induced choroidal neovasculation(CNV) model in the Brown Norway rats.
One eye of 32 rats received a series of 20 spots of laser irradiation(659nm,360mw,50μm, 0.05s),the other eye were as controls.CNV was evaluated by FFA,high molecular weight FITC-Dextran(MW 2×10~6) for high resolution angiography in RPE-choroid-sclera flat mounts, and histopathologic examination is performed in 7,14,21 and 28 days after photocoagulation.
2.To evaluate the changes of choroidal neovasculation(CNV) taking diffent concentration of LiangXueHuaYu decoction,and choose the best concentration.
Both eyes of 24 rats received a series of 20 spots of laser irradiation(659nm,360mw,50μm, 0.05s).The rats were divided into four groups:the control group(6 rats),high concentration traditional Chinese medicine(TCM) group(6 rats),median concentration TCM group(6 rats), low concentration TCM group(6 rats).All rats received supplementation everyday.FFA and histopathologic examination is performed in 7,14 and 21 days after photocoagulation.
3.To evaluate and compare if taking LiangXueHuaYu decoction and intravitreal triamcinolone acetonide(TA) inhibit experimental CNV induced by laser trauma in a rat as a model of choroidal neovascular membranes(CNVMs).
Both eyes of 48 rats received a series of 20 spots of laser irradiation(659nm,360mW, 50μm,0.05s).The rats were randomly divided into three groups:the control group(16 rats), traditional Chinese medicine(TCM) group(16 rats),TA group(16 rats).The control group received 0.9%physiological saline by gastric gavage,the TCM group were administrated LiangXueHuaYu decoction drugs by gastric gavage,and TA group underwent an intravitreous injection with 5uL(0.2mg) of TA.Fundus fluorescein angiography(FFA),histopathologic examination,Ⅷstraining cells by immunohistochemistry and high molecular weight FITC—Dxtran(MW 2×10~6) for high resolution angiography in RPE—choroid—sclera flat mounts were performed on 7,14,21 and 28 days after photocoagulation.
4.To evaluate the changes of MMP-9 and TIMP-2 in CNV model after taking LiangXueHuaYu decoction and triamcinolone acetonide(TA).
Both eyes of 36 rats received a series of 20 spots of laser irradiation(659nm,360mw,50μm, 0.05s).The rats were divided into three groups:the control group(received 0.9% physiological saline by gastric gavage,12 rats),the TCM group(LiangXueHuaYu decoction drugs by gastric gavage,12 rats) and TA group(intravitreous injection with TA 5μl,0.2mg,12 rats).Histopathologic examination(HE),MMP-9 and TIMP-2 straining by immunohistochemistry were performed on 7,14,21 and 28 days after photocoagulation.
RESULTS
Clinical cases observation:
At the end of the follow-up period,in the Chinese medicine group,the BCVA improved 0.21,the BCVA of 33 eyes(71.7%) is higher than 4.7,the vision improved obviously(≥2 lines) in 25eyes(54.3%),kept stable(changed within 1line) in 16 eyes(34.8%),and decreased(≥2 lines) in 5 eyes(10.9%).The results of FFA showed completely closed CNV in 34 eyes(73.9%),partly closed CNV in 7 eyes(15.2%),unclosed CNV in 4 eye(8.7%) and enlarged CNV in 0 eyes.OCT showed scar stage in 38 eyes(82.6%),middle stage in 6 eyes (13.1%) and active stage in 2 eyes(4.4%).In the alignment group,the BCVA improved 0.12, the distribution and the improvement of BCVA,the lesion's diameter and size in FFA,the central retinal thickness and macular volume in OCT were similar with before treatment.The results of FFA showed completely closed CNV in 13 eyes(86.7%),partly closed CNV in 1 eyes(6.7%),unclosed CNV in 0 eye and enlarged CNV in 1 eyes(6.7%).OCT showed scar stage in 13 eyes(86.7%),middle stage in 1 eyes(6.7%) and active stage in 1 eyes(6.7%).In the scar group,there was no significant improve before and after treatment.
Animal experiment study:
1.CNV was firstly appeared on day 7 after photocoagulation,reaching the peak on day 21, no significant progress occurred in 14～28 days.The fluorescein leakage and the thickness of laser-induced CNV were increased from day 7 to day 21,were decreased in day 28.
2.FFA showed that CNV was firstly appeared on day 7 after photocoagulation,reaching the peak on day 21 in control group,but there was no significant progress occurred in TCM groups.The fluorescein leakage of median and low concentration TCM group were significantly less than high concentration TCM group and the control group on day 21.
The variation of CNV in thickness showed that in the control group CNV increases from 7 days to 21 days,and reach the peak on day 21;and in the TCM groups especially in the median concentration TCM group,the CNV increases from 7 days to 14 day,and decreases from 14 days to 21 days.
3.FFA showed that in control guoup the fluorescein leakage ingravescence,the fluorescein leakage were less in TCM group than in control group,and in TA group the scar staining were greatly bigger than the control group.Histologically,the CNV membrane was observed beneath the retina and the factorⅧpositive cells were seen.CNV thickness was firstly appeared on day 7 after photocoagulation,reaching the peak on day 21 in control group,and decreased on 28d.In TCM group,CNV thickness was reaching the peak on day 14,and decreased greatly on 21d,increased again on 28d.And in TA group, the CNV thickness was getting thinner from 7 to 14d,get thinnest on 14d,then the CNV thickness was getting thicker.The staining intensity ofⅧin cellular plasma showed that in control group the staining intensity was reaching the peak on day 14,and then decreased greatly.In TCM group the staining intensity was reaching the peak on day 7, and then decreased greatly.In TA group the staining intensity was reaching the peak on day 14,but the degree was less than the control group,then decreased greatly. Morphologic and quantitative analysis of flat mounts and histologic sections showed that in control group CNV firstly appeared on day 7 after photocoagulation and peaked in day 28,in TCM group CNV peaked on 14d,and decreased significantly on 21d,then increased on 28d.In TA group,CNV was getting bigger from 7 to 14d,but the scars after photocoagulation were obvious on 21,28d.
4.The staining intensity of MMP-9 in CNV showed that in control group the staining intensity was reaching the peak on day 7,and then decreased greatly.In TCM group the staining intensity was reaching the peak on day 14,the peak was lower than the control group and then decreased greatly.In TA group the staining intensity was reaching the peak on day 7,but the degree was between the control group and TCM group,then decreased.A platform stage occur on day 14～21.The TIMP-2's staining intensity showed that in control group the staining intensity was reaching the peak on day 14,and then decreased greatly.In TCM group the staining intensity was reaching the peak on day 14,but the peak was higher than the control group and then decreased greatly.In TA group the staining intensity was reaching the peak on day 14,but the degree was between the control group and the TCM group,then decreased greatly.
CONCLUSIONS
Clinical cases observation:
Chinese medicine of liangxuehuayu is an effective treatment for most patients with CNV caused by CEC,can help the close of CNV after western medicine therapy,perhaps can improve the symptoms of old CEC.
Animal experiment study:
1.The Krypton laser induced model of CNV in the pigment rats may be useful,and the quantitative analysis of FFA and the thickness of CNV are useful for in vivo studies of angiogenesis and its modulation via various therapy.
2.The median concentration LiangXueHuaYu decoction can suppress experimental CNV induced by Krypton laser.
3.Intravitreal injection of triamcinolone acetonide(TA) can inhibit experimental CNV induced by laser trauma in a rat as a model,although on 28d,the scar was obvious.The LiangXueHuaYu decoction can suppress experimental CNV,and the scar was lesser.
4.The LiangXueHuaYu decoction and TA can also suppress experimental CNV induced by Krypton laser through the regulation of MMP-9 and TIMP-2,and the LiangXueHuaYu decoction has a stronger effect to regulate the system of MMPs-TIMPs than TA.
通过临床病例,观察中药凉血化瘀方治疗中心性渗出性脉络膜视网膜病变(centralexudative chorioretinophy,CEC)的疗效。进一步通过动物实验,观察凉血化瘀中药对脉络膜新生血管(choroidal neovascularization,CNV)的影响,并初步探讨其作用机理,为中药凉血化瘀方用于临床治疗CEC提供依据。
方法
一、临床病例观察:
对70例70眼确诊的中心性渗出性脉络膜视网膜病变患者服凉血化瘀方中药治疗,将70眼分为中药组46眼,联合组15眼,陈旧组9眼。服中药3个月,总观察时间9个月。观察比较治疗前后最佳矫正视力(best corrected vision acuity,BCVA)、荧光眼底血管造影(fundus fluorescein angiography,FFA)和光学相干断层扫描(Optic coherenttomography,OCT)图像。
二、动物实验研究:
1.建立CNV动物模型,并评价可行性。
棕色挪威(brown Norway,BN)大鼠32只一眼行氪激光(659nm)眼底光凝,另一眼作空白对照。激光功率、光凝斑直径和曝光时间分别为360mW、50μm及0.05s。光凝20点。分别在光凝后7,14,21,28d随机选取7只大鼠行眼底照像、FFA检查。随机选取1只大鼠行脉络膜血管铺片检查。眼球标本行组织病理切片光镜、Ⅷ免疫组织化学染色观察。
2.评价不同浓度凉血化瘀中药对氪激光诱导BN大鼠CNV形态的影响,从中筛选最佳浓度。
659nm激光诱导BN大鼠CNV模型同1,随机分成空白对照组、高浓度、中浓度和低浓度中药组4组,每组6只,每日不同浓度中药灌胃。四组分别在光凝后7、14、21d随机选取2只大鼠行眼底照像、FFA检查。眼球标本行组织病理切片光镜、Ⅷ免疫组织化学染色观察。
3.比较中浓度凉血化瘀中药与曲胺耐德(triamcinolone acetonide,TA)对氪激光诱导BN大鼠CNV形态的影响。
659nm激光诱导BN大鼠CNV模型同1,随机分成空白对照组(16只),中药组(16只),曲胺耐德组(16只)。空白对照组每日生理盐水灌胃,中药组每日中药灌胃,曲胺耐德组术后第2d玻璃体腔内注射5μL(0.2mg)曲胺耐德。在光凝后7,14,21,28d每组随机选取3只大鼠行荧光素眼底血管造影(FFA)检查,检查后处死,取眼球行HE染色,Ⅷ因子相关抗原免疫组织化学检测;同时,每组选取1只大鼠做脉络膜血管铺片检查。
4.评价凉血化瘀中药及TA对氪激光诱导BN大鼠CNV中基质金属蛋白酶-9(Matrixmetalloproteinase 9,MMP-9)和基质金属蛋白酶抑制剂(tissue inhibitor ofmetalloproteinase 2,TIMP-2)表达的影响。
659nm激光诱导BN大鼠CNV模型同1,随机分成空白对照组,中药组和TA组各12只。分别在光凝后7,14,21,28d随机选取3只大鼠处死,摘除眼球,行病理切片及免疫组织化学检测MMP-9及TIMP-2蛋白在CNV组织中的表达。
结果
一、临床病例观察:
末次随访时,中药组46眼中,视力平均提高0.21,较治疗前有统计意义;视力≥4.7者33眼(71.7%);视力提高≥2行的25眼(54.3%),视力波动在1行以内者16只眼(34.8%),视力下降≥2行的5眼(10.9%),较治疗前视力明显提高。病灶直径、病灶面积,中央视网膜厚度与治疗前相比无统计学意义上的改变,黄斑容积较治疗前降低。FFA检查发现:显效(CNV闭合)34眼(73.9%),有效(CNV部分闭合)7眼(15.2%),进步(CNV小部分闭合)4眼(8.7%),无效(CNV扩大)0眼,较治疗前显著改善。OCT检查发现:CNV型别由治疗前活动期38眼(82.6%)、中间期8眼(17.4%),转变为有效(瘢痕期)38眼(82.6%),进步(中间期)6眼(13.1%),无效(活动期)2眼(4.4%),具有统计学意义。
联合组15眼中,视力平均提高0.12,视力分布及视力提高的情况较治疗前无明显改善,病灶直径、病灶面积、中央视网膜厚度及黄斑容积与治疗前相比均无统计学意义上的变化。FFA检查发现:显效(CNV闭合)13眼(86.7%),有效(CNV部分闭合)1眼(6.7%),无效(CNV扩大)1眼(6.7%),较治疗前显著改善。OCT检查发现:CNV型别由治疗前活动期7眼(46.7%)、中间期4眼(26.7%)、瘢痕期4眼(26.7%)均可出现,转变为有效(瘢痕期)13眼(86.7%),进步(中间期)1眼(6.7%),无效(活动期)1眼(6.7%),具有统计学意义。
陈旧组9眼,治疗后,病人主诉视疲劳的症状减轻,视力平均提高0.11,视力提高≥2行者3眼(33.3%),但是,与治疗前相比无统计学差异。病灶情况与治疗前相比无统计学差异。
二、动物实验研究:
1.659nm激光(360mW,50μm,0.05s)照射BN大鼠视网膜20点后,7～21d显示FFA晚期荧光素渗漏及光镜下CNV厚度逐渐增加,28d时FFA渗漏和CNV厚度开始减少。
2.FFA显示:光凝后7～21d,空白对照组CNV渗漏面积逐渐增大,而中药组渗漏面积增加无明显差异;至21d,中、低浓度中药组渗漏面积明显低于空白对照组和高浓度中药组,以中浓度中药组CNV渗漏面积最小。CNV厚度变化:空白对照组7～2ld逐渐增厚,至21d达到高峰;而中药组至14d CNV厚度达到高峰,14～21d CNV厚度变薄,以中浓度中药组CNV厚度最薄。
3.FFA显示:光凝后7～28d,空白对照组CNV渗漏面积逐渐增大,而中药组渗漏面积略增加,TA组瘢痕着色明显。CNV厚度:空白对照组逐渐增加,至21d达高峰,28d略有下降;中药组CNV厚度逐渐增加,至14d达到高峰,21d时明显变薄,28d再次增加;TA组7～14d时CNV逐渐变薄,至14d时最薄,此后CNV再次增厚。Ⅷ因子相关抗原阳性反应物吸光度:空白对照组7～14d时逐渐增加,至14d达到高峰,此后下降;中药组7d时达到高峰,此后下降;TA组亦是14d达到高峰,但峰值较空白对照组低,此后下降。脉络膜血管铺片CNV面积:空白对照组7～28d逐渐增大;中药组7～14d达到高峰,14～21d下降,28d时再次增加;TA组7～14dCNV面积逐渐增加,21,28d时瘢痕明显。
4.空白对照组在光凝后7d MMP-9达到高峰,此后逐渐下降;中药组在光凝后14d达到高峰,但峰值低于空白对照组,此后逐渐下降;曲胺奈德组在光凝后7d达到高峰,峰值介于空白对照组和中药组之间,此后逐渐下降,在14～21d出现平台期。空白对照组在光凝后14d TIMP-2达到高峰,此后逐渐下降;中药组在光凝后14d达到高峰,峰值高于空白对照组,此后逐渐下降;曲胺奈德组在光凝后14d达到高峰,峰值介于空白对照组和中药组之间,此后下降。
结论
一、临床病例观察:
中药凉血化瘀方可以促进CEC中CNV闭合,可以促进经过西医治疗后仍有CNV渗漏的CEC患者CNV闭合,可能改善陈旧CEC患者的视疲劳症状。
二、动物实验研究:
1.氪激光诱导BN大鼠的CNV模型是一种较为理想的模型,FFA及CNV厚度分析是CNV定量研究的有效手段。
2.中浓度凉血化瘀中药可以有效抑制氪激光诱导BN大鼠的CNV增生,防止CNV渗漏。
3.TA玻璃体腔注射可以明显抑制CNV形成,但后期形成瘢痕明显;凉血化瘀中药灌胃不仅有效抑制CNV增生,而且瘢痕较小。
4.在下调MMP-9,上调TIMP-2的表达进而抑制CNV形成方面,凉血化瘀中药的作用强于TA。
OBJECTIVE
To investigate the therapeutic effect of Chinese medicine of LiangXueHuaYu on central exudative chorioretinopathy(CEC).And to evaluate the changes of choroidal neovasculation (CNV) taking Chinese medicine of LiangXueHuaYu,investigate the possibility of LiangXueHuaYu decoction as a therapeutic agent for experimental CNV induced by Krypton laser in Brown Norway rats,and further to study their mechanism.Through the clinical cases and animal experiment,we hope we can provide the basis for LiangXueHuaYu decoction used in clinic to curing CEC.
METHODS
Clinical cases observation:
The clinical data of 70 patients(70 eyes) with CEC who had followed up for 9 months after therapy of Chinese medicine for CNV were analyzed.The cases were divided into three groups:Chinese medicine group(46 eyes),combined treatment group(15 eyes) and the scar group(9 eyes).The changes of the best corrected visual acuity(BCVA),Fundus Fluorescein Angiography(FFA) and Optic coherent tomography(OCT) were observed and analyzed.
Animal experiment study:
1.To investigate the feasibility of Krypton laser-induced choroidal neovasculation(CNV) model in the Brown Norway rats.
One eye of 32 rats received a series of 20 spots of laser irradiation(659nm,360mw,50μm, 0.05s),the other eye were as controls.CNV was evaluated by FFA,high molecular weight FITC-Dextran(MW 2×10~6) for high resolution angiography in RPE-choroid-sclera flat mounts, and histopathologic examination is performed in 7,14,21 and 28 days after photocoagulation.
2.To evaluate the changes of choroidal neovasculation(CNV) taking diffent concentration of LiangXueHuaYu decoction,and choose the best concentration.
Both eyes of 24 rats received a series of 20 spots of laser irradiation(659nm,360mw,50μm, 0.05s).The rats were divided into four groups:the control group(6 rats),high concentration traditional Chinese medicine(TCM) group(6 rats),median concentration TCM group(6 rats), low concentration TCM group(6 rats).All rats received supplementation everyday.FFA and histopathologic examination is performed in 7,14 and 21 days after photocoagulation.
3.To evaluate and compare if taking LiangXueHuaYu decoction and intravitreal triamcinolone acetonide(TA) inhibit experimental CNV induced by laser trauma in a rat as a model of choroidal neovascular membranes(CNVMs).
Both eyes of 48 rats received a series of 20 spots of laser irradiation(659nm,360mW, 50μm,0.05s).The rats were randomly divided into three groups:the control group(16 rats), traditional Chinese medicine(TCM) group(16 rats),TA group(16 rats).The control group received 0.9%physiological saline by gastric gavage,the TCM group were administrated LiangXueHuaYu decoction drugs by gastric gavage,and TA group underwent an intravitreous injection with 5uL(0.2mg) of TA.Fundus fluorescein angiography(FFA),histopathologic examination,Ⅷstraining cells by immunohistochemistry and high molecular weight FITC—Dxtran(MW 2×10~6) for high resolution angiography in RPE—choroid—sclera flat mounts were performed on 7,14,21 and 28 days after photocoagulation.
4.To evaluate the changes of MMP-9 and TIMP-2 in CNV model after taking LiangXueHuaYu decoction and triamcinolone acetonide(TA).
Both eyes of 36 rats received a series of 20 spots of laser irradiation(659nm,360mw,50μm, 0.05s).The rats were divided into three groups:the control group(received 0.9% physiological saline by gastric gavage,12 rats),the TCM group(LiangXueHuaYu decoction drugs by gastric gavage,12 rats) and TA group(intravitreous injection with TA 5μl,0.2mg,12 rats).Histopathologic examination(HE),MMP-9 and TIMP-2 straining by immunohistochemistry were performed on 7,14,21 and 28 days after photocoagulation.
RESULTS
Clinical cases observation:
At the end of the follow-up period,in the Chinese medicine group,the BCVA improved 0.21,the BCVA of 33 eyes(71.7%) is higher than 4.7,the vision improved obviously(≥2 lines) in 25eyes(54.3%),kept stable(changed within 1line) in 16 eyes(34.8%),and decreased(≥2 lines) in 5 eyes(10.9%).The results of FFA showed completely closed CNV in 34 eyes(73.9%),partly closed CNV in 7 eyes(15.2%),unclosed CNV in 4 eye(8.7%) and enlarged CNV in 0 eyes.OCT showed scar stage in 38 eyes(82.6%),middle stage in 6 eyes (13.1%) and active stage in 2 eyes(4.4%).In the alignment group,the BCVA improved 0.12, the distribution and the improvement of BCVA,the lesion's diameter and size in FFA,the central retinal thickness and macular volume in OCT were similar with before treatment.The results of FFA showed completely closed CNV in 13 eyes(86.7%),partly closed CNV in 1 eyes(6.7%),unclosed CNV in 0 eye and enlarged CNV in 1 eyes(6.7%).OCT showed scar stage in 13 eyes(86.7%),middle stage in 1 eyes(6.7%) and active stage in 1 eyes(6.7%).In the scar group,there was no significant improve before and after treatment.
Animal experiment study:
1.CNV was firstly appeared on day 7 after photocoagulation,reaching the peak on day 21, no significant progress occurred in 14～28 days.The fluorescein leakage and the thickness of laser-induced CNV were increased from day 7 to day 21,were decreased in day 28.
2.FFA showed that CNV was firstly appeared on day 7 after photocoagulation,reaching the peak on day 21 in control group,but there was no significant progress occurred in TCM groups.The fluorescein leakage of median and low concentration TCM group were significantly less than high concentration TCM group and the control group on day 21.
The variation of CNV in thickness showed that in the control group CNV increases from 7 days to 21 days,and reach the peak on day 21;and in the TCM groups especially in the median concentration TCM group,the CNV increases from 7 days to 14 day,and decreases from 14 days to 21 days.
3.FFA showed that in control guoup the fluorescein leakage ingravescence,the fluorescein leakage were less in TCM group than in control group,and in TA group the scar staining were greatly bigger than the control group.Histologically,the CNV membrane was observed beneath the retina and the factorⅧpositive cells were seen.CNV thickness was firstly appeared on day 7 after photocoagulation,reaching the peak on day 21 in control group,and decreased on 28d.In TCM group,CNV thickness was reaching the peak on day 14,and decreased greatly on 21d,increased again on 28d.And in TA group, the CNV thickness was getting thinner from 7 to 14d,get thinnest on 14d,then the CNV thickness was getting thicker.The staining intensity ofⅧin cellular plasma showed that in control group the staining intensity was reaching the peak on day 14,and then decreased greatly.In TCM group the staining intensity was reaching the peak on day 7, and then decreased greatly.In TA group the staining intensity was reaching the peak on day 14,but the degree was less than the control group,then decreased greatly. Morphologic and quantitative analysis of flat mounts and histologic sections showed that in control group CNV firstly appeared on day 7 after photocoagulation and peaked in day 28,in TCM group CNV peaked on 14d,and decreased significantly on 21d,then increased on 28d.In TA group,CNV was getting bigger from 7 to 14d,but the scars after photocoagulation were obvious on 21,28d.
4.The staining intensity of MMP-9 in CNV showed that in control group the staining intensity was reaching the peak on day 7,and then decreased greatly.In TCM group the staining intensity was reaching the peak on day 14,the peak was lower than the control group and then decreased greatly.In TA group the staining intensity was reaching the peak on day 7,but the degree was between the control group and TCM group,then decreased.A platform stage occur on day 14～21.The TIMP-2's staining intensity showed that in control group the staining intensity was reaching the peak on day 14,and then decreased greatly.In TCM group the staining intensity was reaching the peak on day 14,but the peak was higher than the control group and then decreased greatly.In TA group the staining intensity was reaching the peak on day 14,but the degree was between the control group and the TCM group,then decreased greatly.
CONCLUSIONS
Clinical cases observation:
Chinese medicine of liangxuehuayu is an effective treatment for most patients with CNV caused by CEC,can help the close of CNV after western medicine therapy,perhaps can improve the symptoms of old CEC.
Animal experiment study:
1.The Krypton laser induced model of CNV in the pigment rats may be useful,and the quantitative analysis of FFA and the thickness of CNV are useful for in vivo studies of angiogenesis and its modulation via various therapy.
2.The median concentration LiangXueHuaYu decoction can suppress experimental CNV induced by Krypton laser.
3.Intravitreal injection of triamcinolone acetonide(TA) can inhibit experimental CNV induced by laser trauma in a rat as a model,although on 28d,the scar was obvious.The LiangXueHuaYu decoction can suppress experimental CNV,and the scar was lesser.
4.The LiangXueHuaYu decoction and TA can also suppress experimental CNV induced by Krypton laser through the regulation of MMP-9 and TIMP-2,and the LiangXueHuaYu decoction has a stronger effect to regulate the system of MMPs-TIMPs than TA.
引文
1.Spaide RF.Choroidal neovascularization in younger patients.Curr Opin Ophthalmol.1999Jun;10(3):177-81.Review.
2.Cohen SY,Laroche A,Leguen Y,et al.Etiology of choroidal neovascularization in young patients.Ophthalmology.1996 Aug;103(8):1241-4.
3.Ho AC,Yannuzzi LA,Pisicano K,DeRosa J.The natural history of idiopathic subfoveal choroidal neovascularization.Ophthalmology.1995 May;102(5):782-9.
4.Lindblom B,Andersson T.The prognosis of idiopathic choroidal neovascularization in persons younger than 50 years of age.Ophthalmology.1998 Oct;105(10):1816-20.
5.Iida T,Hagimura N,Kishi S,Shimizu K.Indocyanine green angiographic features of idiopathic submacular choroidal neovascularization.Am J Ophthalmol.1998 Jul;126(1):70-6.
6.Shiraga F,Shiragami C.,Matsuo T,et al.Identification of ingrowth site of idiopathic subfoveal choroidal neovascularization by indocyanine green angiography.Ophthalmology,2000,mar;107(3):600
7．韩梅、陈松、时翼川等．中心性渗出性脉络膜视网膜病变ICGA与FFA的对比关系．眼科研究,2004,22(1)：86-88．
8.Fukuchi T,Takahashi K,Ida H,Sho K,Matsumura M.Staging of idiopathic choroidal neovascularization by optical coherence tomography.Graefes Arch Clin Exp Ophthalmol.2001 Jul;239(6):424-9.
9.Grossniklaus HE,Green WR.Histopathologic and ultrastructural findings of surgically excised choroidal neovascularization.Submacular Surgery Trials Research Group.Arch Ophthalmol.1998 Jun;116(6):745-9.
10.Otani A,Takagi H,Oh H,et al.Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes.Invest Ophthalmol Vis Sci.1999 Aug;40(9):1912-20.
11.Cui JZ,Hornan D,Potter MJ,et al.The role of leptin in choroidal neovascularization.Am J Ophthalmol.2001 Nov;132(5):792-4.
12.Maberley D,Cui JZ,Morris A,et al.Expression of leptin and neuropilin in a case of idiopathic choroidal neovascularization.Can J Ophthalmol.2002 Aug;37(5):295-300.
13.Cui JZ,Hinz BJ,Greve MD,et al.Expression of neuropilin-1 in choroidal neovascular membranes.Can J Ophthalmol.2003 Feb;38(1):41-5.
14.Sato T,Kanda T,Iida T,et al.Immunohistochemical study of surgically excised choroidal neovascular membranes.J Int Med Res.2003 Sep-Oct;31(5):402-6.
15.Grossniklaus HE,Miskala PH,Green WR,et al.Histopathologic and ultrastructural features of surgically excised subfoveal choroidal neovascular lesions:submacular surgery trials report no.7.Arch Ophthalmol.2005 Jul;123(7):914-21.
16.Laser photocoagulation for juxtafoveal choroidal neovascularization.Five-year result from randomized clinical trials.Macular Photocoagulation Study Group.Arch Ophthalmol.1994;112:500-509.
17.Laser photocoagulation for neovascular lesions nasal to the fovea.Results from clinical trials for lesions secondary to ocular histoplasmosis or idiopathic causes.Macular Photocoagulation Study Group.Arch Ophthalmol.1995 Jan;l13(1):56-61.
18.Hawkins BS,Bressler NM,Bressler SB,et al.Surgical removal vs observation for subfoveal choroidal neovascularization,either associated with the ocular histoplasmosis syndrome or idiopathic:I.Ophthalmic findings from a randomized clinical trial:Submacular Surgery Trials(SST) Group H Trial:SST Report No.9.Arch Ophthalmol.2004Nov;122(11):1597-611.
19.Bains HS,Patel MR,Singh H,Marcus DM.Surgical treatment of extensive peripapillary choroidal neovascularization in elderly patients.Retina.2003 Aug;23(4):469-74.
20.Kumar A,Prakash G,Singh RP.Transpupillary thermotherapy for idiopathic subfoveal choroidal neovascularization.Acta Ophthalmol Scand.2004 Apr;82(2):205-8.
21.Wachtlin J,Wehner A,Heimann H,et al.Photodynamic treatment with verteporfin for patients with idiopathic choroidal neovascularization.Two-year results.Ophthalmologe.2004May;101(5):489-95.
22.Yoo MH,Boo HD,Kim HK.Result of photodynamic therapy for idiopathic subfoveal choroidal neovascularization.Korean J Ophthalmol.2005 Dec;19(4):264-8.
23.Ruiz-Moreno JM,Montero JA,Arias L,et al.Photodynamic therapy in subfoveal and juxtafoveal idiopathic and postinflammatory choroidal neovascularization.Acta Ophthalmol Scand.2006 Dec;84(6):743-8.
24.Postelmans L,Pasteels B,Coquelet P,et al.Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females.Am J Ophthalmol.2004 Nov;138(5):803-8.
25.黎晓新、赵明威、曲进锋.特发性脉络膜新生血管采用光动力疗法后视网膜色素上皮损伤的研究.中华眼科杂志,2007:43(3):206-211.
26.Giovannini A,Neri P,Mercanti L,Bruè C.Photodynamic treatment versus photodynamic treatment associated with systemic steroids for idiopathic choroidal neovascularisation.Br J Ophthalmol.2007 May;91(5):620-3.
27.Pedersen R,Soliman W,Lund-Andersen H,Larsen M.Treatment of choroidal neovascularization using intravitreal bevacizumab.Acta Ophthalmol Scand.2007 May 18; [Epub ahead of print]
28.Chan WM,Lai TY,Liu DT,Lam DS.Intravitreal bevacizumab(avastin) for choroidal neovascularization secondary to central serous chorioretinopathy,secondary to punctate inner choroidopathy,or of idiopathic origin.Am J Ophthalmol.2007 Jun;143(6):977-983.Epub 2007 Apr
29.Mandal S,Garg S,Venkatesh P,Mithal C,Vohra R,Mehrotra A.Intravitreal bevacizumab for subfoveal idiopathic choroidal neovascularization.Arch Ophthalmol.2007Nov;125(11):1487-92.
30.罗国芬,主编.陈达夫中医眼科临床经验[M].成都:四川科学出版社,1985.46-58.
31.吉洁,丁淑华.健脾益气法治疗脉络膜新生血管黄斑病变30例.新中医,2008,40(1):80-82.
32.钱芳,施伟.二陈汤加减治疗中心性渗出性脉络膜视网膜炎.中华现代中西医杂志,2004,2(6):548-549.
33.刘文舟,郑媛,黄浩成.中西医结合治疗中心性渗出性脉络膜视网膜炎25例.国际眼科杂志,2003,3(3):136-137.
34.杨旭,刘征.中西医结合治疗中心性渗出性脉络膜视网膜病变.辽宁中医杂志,2001,28(5):299.
35.曾平.清热化痰与活血散结法在治疗中心性渗出性脉络膜视网膜炎中的作用.中国中医眼科杂志,2001,11(3):156.
36.黄叔仁,张晓峰.中药治疗中心性渗出性脉络膜视网膜炎临床观察.中国中医眼科杂志,1997,7(1):10-12.
37.杨兴华.辨证治疗中心性渗出性脉络膜视网膜炎.南京中医药大学学报,2004,20(4):241-242.
38.于晓林,王明芳.中心性渗出性脉络膜视网膜炎辨证论治.附:83例89眼病例报告.成都中医药大学学报,2004,27(4):16-17.
39.唐由之,李学晶,王影.凉血化瘀中药治疗中心性渗出性脉络膜视网膜病变临床观察.中医杂志,2007;48(12):1099.
40.Mimouni KF,Bressler SB,Bressler NM.Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in children.Am J Ophthalmol.2003 Jun;135(6):900-2.
1.李凤鸣.眼科全书.北京:人民卫生出版社,1997:2271-2272.
2.唐由之,李学晶,王影.凉血化瘀中药治疗中心性渗出性脉络膜视网膜病变临床观察.中医杂志2007;48(12):1099.
3.李学晶,唐由之.凉血化瘀中药治疗中心性渗出性脉络膜视网膜病变疗效观察.中国中医眼科杂志,2009,19(1):21-23.
4.张美霞,严密,唐健,等.光动力疗法治疗中心性渗出性脉络膜视网膜病变疗效观察.中华眼底病杂志2007;23(1):17-20.
5.Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-yaer results from randomized clinical trials.Macular Photocoagulation Study Group.Arch Ophthalmol 1994;112:500-509.
6.Hawkins BS,Bressler NM,Bressler SB,et al.Sugical removal vs observation for subfoveal choroidal neovascularization,either associated with the ocular histoplasmosis syndrome or idiopathic submacular surgery trails(SST)group H trail:SST Report No.9.
7.Kato A,Kimura H,Okabe K,et al.Suppression of laser-induced choroidal neovascularization by posterior sub-tenom administration of triamcinolone acetonide.Retina 2005;25:503-509.
8.王雨生,严密.黄斑变性患者的希望—评2006年度十大科学进展之一.中华眼底病杂志,2007,23(1):1-3.
9.Yoo MH,Boo HD,Kim HK.Result of photodynamic therapy for idiopathic subfoveal choroidal neovascularization.Korean J Ophthalmol 2005,19:264-268.
10.Wachtlin J,Wehner A,Heimann H,et al.Photodynamic treatment with verteporfin for patients with idiopathic choroidal neovascularization.Two-year results.Ophthalmologe 2004;101(5):489-95.
11.Chen YS,Lin JY,Tseng SY,Tang HF,Lee HJ,Lin YR.Photodynamic therapy of idiopathic subfoveal choroidal neovascularization in Taiwanese patients:a 2-year follow-up.Eye.2009 Feb;23(2):314-9.Epub 2008 Jan 18.
12.苏兆安,姚克,沈洁,等.特发性脉络膜新生血管光动力疗法的疗效观察.中华眼科杂志,2007,43(6):509-513.
13.Mandal S,Garg S,Venkatesh P,Mithal C,Vohra R,Mehrotra A.Intravitreal bevacizumab for subfoveal idiopathic choroidal neovascularization.Arch Ophthalmol.2007Nov;125(11):1487-92.
14.黎晓新,赵明威,曲进锋.特发性脉络膜新生血管采用光动力疗法后视网膜色素上皮损伤的研究.中华眼底病杂志2007;23(3):206-211.
15.Fukuchi T,et al.Staging of idiopathic choroidal neovascularization by optical coherence tomography.Graefe's Arch Clin Exp Ophthalmol 2001.239:424.
16.刘杏.眼科临床光学相干断层成像学.广东:广东科技出版社,2007.118-9.
17.Gass JDM.Biomicroscopic and histologic considerations regarding the feasibility of surgical excision of subforveal neovascular membranes.Am J Ophthalmol,1994,18:285.
18.钱芳,施伟.二陈汤加减治疗中心性渗出性脉络膜视网膜炎.中华现代中西医杂志,2004,2(6):548-549.
19.吉洁,丁淑华.健脾益气法治疗脉络膜新生血管黄斑病变30例.新中医,2008,40(1):80-82.
20.杨兴华.辨证治疗中心性渗出性脉络膜视网膜炎.南京中医药大学学报,2004,20(4):241-242.
21.曾平.清热化痰与活血散结法在治疗中心性渗出性脉络膜视网膜炎中的作用.中国中医眼科杂志,2001,11(3):156.
22.刘文舟,郑媛,黄浩成.中西医结合治疗中心性渗出性脉络膜视网膜炎25例.国际眼科杂志,2003,3(3):136.137.
23.杨旭,刘征.中西医结合治疗中心性渗出性脉络膜视网膜病变.辽宁中医杂志,2001,28(5):299.
24.于晓林,王明芳.中心性渗出性脉络膜视网膜炎辨证论治.附:83例89眼病例报告.成都中医药大学学报,2004,27(4):16-17.
25.刘军,赖铭莹,曾平,等.玻璃体腔注射Avastin联合中药治疗中心性渗出性脉络膜视网膜病变初步临床观察.中国中医眼科杂志,2009,19(2):30-32.
26.聂爱光.现代黄斑疾病诊断治疗学.北京:北京医科大学,中国协和医科大学联合出版社.1996.398-401.
1 王雨生,主编.脉络膜新生血管性疾病.北京:人民卫生出版社,2007:160-175
2 Jiang W,Chiou GCY.The development of age-related maculardegeneration (AMD)experimental models.Int J Ophthalmol 2007;7(3):585-589
3 Edelman JL,Castro M.Quantitative image analysis of laser-induced choroidal neovascularization in rat.Exp Eye Res 2000;71(5):523-533
4 Zhang H,Liu ZL.Suppression of experimental choroidal neovaseularization utilizing anti-FLK1 monoclonal antibody.Int J Ophthalmol 2007;7(4):891-894
5 Xu JF,Wang YS.Review of glucocorticoid and diseases with choroidal neovascularization.Int J Ophthalmol 2007;7(3):772-775
6 何花,张红,赵春明,等.激光诱导的实验性脉络膜新生血管模型的定量研究.眼科研究2007;25(1):18-22
7 D' Amato R,Wesolowski E,Smith LE.Microscopic visualization of the retina by angiography with high-molecular-weitht gluorescein-labeled dextrans in the mouse.Microvasc Res 1993;46(2):135-142
8 杨秀梅,王雨生,徐建峰,等.激光诱导有色大鼠脉络膜新生血管的形态学观察.眼科新进展2006;27(3):161-166
1 王雨生,主编.脉络膜新生血管性疾病[M].北京:人民卫生出版社,2007.8-9.
2 唐由之,李学晶,王影.凉血化瘀中药治疗中心性渗出性脉络膜视网膜病变临床观察[J].中医杂志,2007;48(12):1099.
3 王晓庆,梁中琴,等.槲皮素抑制血管生成作用的实验研究[J].中国药理学通报,2004.20(10):1161-4.
4 Thaloor D.Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curvumin[J].Cell Growth Differ,1998,9(4):305.
5 李景恒,黄萍,詹宇坚,等.三七和丹参对视网膜新生血管化小鼠血管内皮细胞生长因子的影响[J].中国临床康复,2005,9(30):96-97.
6 李景恒,黄萍,彭耀崧.三七和丹参对视网膜新生血管化小鼠ICAM-1表达的影响 [J].中华现代眼科学杂志,2005,2(6):522-523.
7 高冬,宋军,胡娟,等.活血化瘀中药对鸡胚绒毛尿囊膜血管生成的影响.中国中西医结合杂志,2005,25(10):912-915.
1 徐建锋,王雨生,杨秀梅,等.地塞米松-聚乳酸-羟基乙酸纳米粒玻璃体内注射对激光诱导的大鼠脉络膜新生血管的抑制作用.中华眼底病杂志2007;23(1):33-37
2 CJulia TA,Criswell MH,Danis RP,et al.Choroidal veovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants.Br J 0phthalmol2003;87:1032-1037
3 Mandal S,Garg S,Venkatesh P,et al.Intravitreal Bevacizumab for Subfoveal Idiopathic Choroidal Neovascularization.Arch Ophthalmol.2007;125(11):1487-1492
4 Krzystolik MG,Afshari MA,Adamis AP,et al.Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.Arch Ophthal -mol2002;120(3):338-346
5 Olson JL,Courtney RJ,Mandava N.Intravitreal Infliximab and Choroidal Neovascularization in an Animal Model.Arch Ophthalmol 2007;125(9):1221-1224
6 Zhang H,Liu ZL.Suppression of experimental choroidal neovaseularization utilizing anti-FLK1 monoclonal antibody.Int J Ophthalmol 2007;7(4):891-894
7 王晓庆,梁中琴,等.槲皮素抑制血管生成作用的实验研究.中国药理学通报2004,20(10):1161-4
8 Thaloor D.Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curvumin[J].Cell Growth Differ,1998,9(4):305.
9 李景恒,黄萍,詹宇坚,等.三七和丹参对视网膜新生血管化小鼠血管内皮细胞生长因子的影响.中国临床康复2005,9(30):96-97
10 李景恒,黄萍,彭耀崧.三七和丹参对视网膜新生血管化小鼠ICAM-1表达的影响.中 华现代眼科学杂志2005,2(6):522-523
11 何花,张虹,赵春明,等.激光诱导的实验性脉络膜新生血管模型的定量研究.眼科研究2007;25(1):18-21
12 CiullaTA,Criswell MH,Danis RP,et al.Intravitreal Triamcinolone Acetonide Inhibits Choroidal Neovascularizationin a Laser-Treated Rat Model.Arch Ophthalmol.2001;119:399-404
13 兰兰,徐建锋,王雨生.糖皮质激素抑制脉络膜新生血管的信号通道.眼科新进展2007;27(12):940-944
14 高冬,宋军,胡娟,等.活血化瘀中药对鸡胚绒毛尿囊膜血管生成的影响.中国中西医结合杂志2005:25(10):912-915
1 Campochiaro PA,Soloway P,Ryan SJ,et al.The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration.Mol Vis 1999;5(11):34-38
2 Hartnett M E,Lappas A,Darland D,et al.Retinal pigment epithelium and endothelial cell interaction causes retinal pigment epithelial barrier dysfunction via a soluble VEGF dependent mechanism.Exp Eye Res 2003;77(5):593-599
3 Tatar O,Adam A,Shinoda K,et al.Matrix metalloproteinases in human choroidal neovascular membranes excised following verteporfin photodynamic therapy.Br J Ophthalmol 2007;91(3):1183-1189
4 曾军,姜德咏,刘湘平,等.MMP-2和MMP-9在脉络膜新生血管膜的表达.眼科新进展2004;24(6):455-457
5 Kvanta A,Shen WY,Sarman S,et al.Matrix metalloproteinase(MMP)expression in experimental choroidal neovascularization.Cur Eye Res 2000;21(3):684-690
6 张士胜,王康孙,王玲,等.MMP-9及TIMP-3在小鼠脉络膜新生血管形成中的作用.上海第二医科大学学报2003,23(3):206-209
7 Harkness KA,Adamson P,Sussman JD,et al.Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium.Brain 2000;123(Pt4):698-709
8 Bradey ME,Cheng LY,Bartsch DU,et al.Preventive versus treatment effect of Ag3340,a potent matrix metalloproteinase inhibitor in a rat model of choroidal neovascularization.J Ocul Pharmacol Ther 2004;20(3):217-237
9 Lambert V.Wielockx B,Munaut C.,et al.MMP-2 and MMP-9 synergize in promoting ehoroidal neovaseularization.FASEB J 2003;17(1):2290-2292
10 Murata T,Cui J,Taba KE.et al.The possibility of gene therapy for the treatment of choroidal neovascularization.0phthalmology2000,107(7):1364-1373
2.Cohen SY,Laroche A,Leguen Y,et al.Etiology of choroidal neovascularization in young patients.Ophthalmology.1996 Aug;103(8):1241-4.
3.Ho AC,Yannuzzi LA,Pisicano K,DeRosa J.The natural history of idiopathic subfoveal choroidal neovascularization.Ophthalmology.1995 May;102(5):782-9.
4.Lindblom B,Andersson T.The prognosis of idiopathic choroidal neovascularization in persons younger than 50 years of age.Ophthalmology.1998 Oct;105(10):1816-20.
5.Iida T,Hagimura N,Kishi S,Shimizu K.Indocyanine green angiographic features of idiopathic submacular choroidal neovascularization.Am J Ophthalmol.1998 Jul;126(1):70-6.
6.Shiraga F,Shiragami C.,Matsuo T,et al.Identification of ingrowth site of idiopathic subfoveal choroidal neovascularization by indocyanine green angiography.Ophthalmology,2000,mar;107(3):600
7．韩梅、陈松、时翼川等．中心性渗出性脉络膜视网膜病变ICGA与FFA的对比关系．眼科研究,2004,22(1)：86-88．
8.Fukuchi T,Takahashi K,Ida H,Sho K,Matsumura M.Staging of idiopathic choroidal neovascularization by optical coherence tomography.Graefes Arch Clin Exp Ophthalmol.2001 Jul;239(6):424-9.
9.Grossniklaus HE,Green WR.Histopathologic and ultrastructural findings of surgically excised choroidal neovascularization.Submacular Surgery Trials Research Group.Arch Ophthalmol.1998 Jun;116(6):745-9.
10.Otani A,Takagi H,Oh H,et al.Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes.Invest Ophthalmol Vis Sci.1999 Aug;40(9):1912-20.
11.Cui JZ,Hornan D,Potter MJ,et al.The role of leptin in choroidal neovascularization.Am J Ophthalmol.2001 Nov;132(5):792-4.
12.Maberley D,Cui JZ,Morris A,et al.Expression of leptin and neuropilin in a case of idiopathic choroidal neovascularization.Can J Ophthalmol.2002 Aug;37(5):295-300.
13.Cui JZ,Hinz BJ,Greve MD,et al.Expression of neuropilin-1 in choroidal neovascular membranes.Can J Ophthalmol.2003 Feb;38(1):41-5.
14.Sato T,Kanda T,Iida T,et al.Immunohistochemical study of surgically excised choroidal neovascular membranes.J Int Med Res.2003 Sep-Oct;31(5):402-6.
15.Grossniklaus HE,Miskala PH,Green WR,et al.Histopathologic and ultrastructural features of surgically excised subfoveal choroidal neovascular lesions:submacular surgery trials report no.7.Arch Ophthalmol.2005 Jul;123(7):914-21.
16.Laser photocoagulation for juxtafoveal choroidal neovascularization.Five-year result from randomized clinical trials.Macular Photocoagulation Study Group.Arch Ophthalmol.1994;112:500-509.
17.Laser photocoagulation for neovascular lesions nasal to the fovea.Results from clinical trials for lesions secondary to ocular histoplasmosis or idiopathic causes.Macular Photocoagulation Study Group.Arch Ophthalmol.1995 Jan;l13(1):56-61.
18.Hawkins BS,Bressler NM,Bressler SB,et al.Surgical removal vs observation for subfoveal choroidal neovascularization,either associated with the ocular histoplasmosis syndrome or idiopathic:I.Ophthalmic findings from a randomized clinical trial:Submacular Surgery Trials(SST) Group H Trial:SST Report No.9.Arch Ophthalmol.2004Nov;122(11):1597-611.
19.Bains HS,Patel MR,Singh H,Marcus DM.Surgical treatment of extensive peripapillary choroidal neovascularization in elderly patients.Retina.2003 Aug;23(4):469-74.
20.Kumar A,Prakash G,Singh RP.Transpupillary thermotherapy for idiopathic subfoveal choroidal neovascularization.Acta Ophthalmol Scand.2004 Apr;82(2):205-8.
21.Wachtlin J,Wehner A,Heimann H,et al.Photodynamic treatment with verteporfin for patients with idiopathic choroidal neovascularization.Two-year results.Ophthalmologe.2004May;101(5):489-95.
22.Yoo MH,Boo HD,Kim HK.Result of photodynamic therapy for idiopathic subfoveal choroidal neovascularization.Korean J Ophthalmol.2005 Dec;19(4):264-8.
23.Ruiz-Moreno JM,Montero JA,Arias L,et al.Photodynamic therapy in subfoveal and juxtafoveal idiopathic and postinflammatory choroidal neovascularization.Acta Ophthalmol Scand.2006 Dec;84(6):743-8.
24.Postelmans L,Pasteels B,Coquelet P,et al.Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females.Am J Ophthalmol.2004 Nov;138(5):803-8.
25.黎晓新、赵明威、曲进锋.特发性脉络膜新生血管采用光动力疗法后视网膜色素上皮损伤的研究.中华眼科杂志,2007:43(3):206-211.
26.Giovannini A,Neri P,Mercanti L,Bruè C.Photodynamic treatment versus photodynamic treatment associated with systemic steroids for idiopathic choroidal neovascularisation.Br J Ophthalmol.2007 May;91(5):620-3.
27.Pedersen R,Soliman W,Lund-Andersen H,Larsen M.Treatment of choroidal neovascularization using intravitreal bevacizumab.Acta Ophthalmol Scand.2007 May 18; [Epub ahead of print]
28.Chan WM,Lai TY,Liu DT,Lam DS.Intravitreal bevacizumab(avastin) for choroidal neovascularization secondary to central serous chorioretinopathy,secondary to punctate inner choroidopathy,or of idiopathic origin.Am J Ophthalmol.2007 Jun;143(6):977-983.Epub 2007 Apr
29.Mandal S,Garg S,Venkatesh P,Mithal C,Vohra R,Mehrotra A.Intravitreal bevacizumab for subfoveal idiopathic choroidal neovascularization.Arch Ophthalmol.2007Nov;125(11):1487-92.
30.罗国芬,主编.陈达夫中医眼科临床经验[M].成都:四川科学出版社,1985.46-58.
31.吉洁,丁淑华.健脾益气法治疗脉络膜新生血管黄斑病变30例.新中医,2008,40(1):80-82.
32.钱芳,施伟.二陈汤加减治疗中心性渗出性脉络膜视网膜炎.中华现代中西医杂志,2004,2(6):548-549.
33.刘文舟,郑媛,黄浩成.中西医结合治疗中心性渗出性脉络膜视网膜炎25例.国际眼科杂志,2003,3(3):136-137.
34.杨旭,刘征.中西医结合治疗中心性渗出性脉络膜视网膜病变.辽宁中医杂志,2001,28(5):299.
35.曾平.清热化痰与活血散结法在治疗中心性渗出性脉络膜视网膜炎中的作用.中国中医眼科杂志,2001,11(3):156.
36.黄叔仁,张晓峰.中药治疗中心性渗出性脉络膜视网膜炎临床观察.中国中医眼科杂志,1997,7(1):10-12.
37.杨兴华.辨证治疗中心性渗出性脉络膜视网膜炎.南京中医药大学学报,2004,20(4):241-242.
38.于晓林,王明芳.中心性渗出性脉络膜视网膜炎辨证论治.附:83例89眼病例报告.成都中医药大学学报,2004,27(4):16-17.
39.唐由之,李学晶,王影.凉血化瘀中药治疗中心性渗出性脉络膜视网膜病变临床观察.中医杂志,2007;48(12):1099.
40.Mimouni KF,Bressler SB,Bressler NM.Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in children.Am J Ophthalmol.2003 Jun;135(6):900-2.
1.李凤鸣.眼科全书.北京:人民卫生出版社,1997:2271-2272.
2.唐由之,李学晶,王影.凉血化瘀中药治疗中心性渗出性脉络膜视网膜病变临床观察.中医杂志2007;48(12):1099.
3.李学晶,唐由之.凉血化瘀中药治疗中心性渗出性脉络膜视网膜病变疗效观察.中国中医眼科杂志,2009,19(1):21-23.
4.张美霞,严密,唐健,等.光动力疗法治疗中心性渗出性脉络膜视网膜病变疗效观察.中华眼底病杂志2007;23(1):17-20.
5.Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-yaer results from randomized clinical trials.Macular Photocoagulation Study Group.Arch Ophthalmol 1994;112:500-509.
6.Hawkins BS,Bressler NM,Bressler SB,et al.Sugical removal vs observation for subfoveal choroidal neovascularization,either associated with the ocular histoplasmosis syndrome or idiopathic submacular surgery trails(SST)group H trail:SST Report No.9.
7.Kato A,Kimura H,Okabe K,et al.Suppression of laser-induced choroidal neovascularization by posterior sub-tenom administration of triamcinolone acetonide.Retina 2005;25:503-509.
8.王雨生,严密.黄斑变性患者的希望—评2006年度十大科学进展之一.中华眼底病杂志,2007,23(1):1-3.
9.Yoo MH,Boo HD,Kim HK.Result of photodynamic therapy for idiopathic subfoveal choroidal neovascularization.Korean J Ophthalmol 2005,19:264-268.
10.Wachtlin J,Wehner A,Heimann H,et al.Photodynamic treatment with verteporfin for patients with idiopathic choroidal neovascularization.Two-year results.Ophthalmologe 2004;101(5):489-95.
11.Chen YS,Lin JY,Tseng SY,Tang HF,Lee HJ,Lin YR.Photodynamic therapy of idiopathic subfoveal choroidal neovascularization in Taiwanese patients:a 2-year follow-up.Eye.2009 Feb;23(2):314-9.Epub 2008 Jan 18.
12.苏兆安,姚克,沈洁,等.特发性脉络膜新生血管光动力疗法的疗效观察.中华眼科杂志,2007,43(6):509-513.
13.Mandal S,Garg S,Venkatesh P,Mithal C,Vohra R,Mehrotra A.Intravitreal bevacizumab for subfoveal idiopathic choroidal neovascularization.Arch Ophthalmol.2007Nov;125(11):1487-92.
14.黎晓新,赵明威,曲进锋.特发性脉络膜新生血管采用光动力疗法后视网膜色素上皮损伤的研究.中华眼底病杂志2007;23(3):206-211.
15.Fukuchi T,et al.Staging of idiopathic choroidal neovascularization by optical coherence tomography.Graefe's Arch Clin Exp Ophthalmol 2001.239:424.
16.刘杏.眼科临床光学相干断层成像学.广东:广东科技出版社,2007.118-9.
17.Gass JDM.Biomicroscopic and histologic considerations regarding the feasibility of surgical excision of subforveal neovascular membranes.Am J Ophthalmol,1994,18:285.
18.钱芳,施伟.二陈汤加减治疗中心性渗出性脉络膜视网膜炎.中华现代中西医杂志,2004,2(6):548-549.
19.吉洁,丁淑华.健脾益气法治疗脉络膜新生血管黄斑病变30例.新中医,2008,40(1):80-82.
20.杨兴华.辨证治疗中心性渗出性脉络膜视网膜炎.南京中医药大学学报,2004,20(4):241-242.
21.曾平.清热化痰与活血散结法在治疗中心性渗出性脉络膜视网膜炎中的作用.中国中医眼科杂志,2001,11(3):156.
22.刘文舟,郑媛,黄浩成.中西医结合治疗中心性渗出性脉络膜视网膜炎25例.国际眼科杂志,2003,3(3):136.137.
23.杨旭,刘征.中西医结合治疗中心性渗出性脉络膜视网膜病变.辽宁中医杂志,2001,28(5):299.
24.于晓林,王明芳.中心性渗出性脉络膜视网膜炎辨证论治.附:83例89眼病例报告.成都中医药大学学报,2004,27(4):16-17.
25.刘军,赖铭莹,曾平,等.玻璃体腔注射Avastin联合中药治疗中心性渗出性脉络膜视网膜病变初步临床观察.中国中医眼科杂志,2009,19(2):30-32.
26.聂爱光.现代黄斑疾病诊断治疗学.北京:北京医科大学,中国协和医科大学联合出版社.1996.398-401.
1 王雨生,主编.脉络膜新生血管性疾病.北京:人民卫生出版社,2007:160-175
2 Jiang W,Chiou GCY.The development of age-related maculardegeneration (AMD)experimental models.Int J Ophthalmol 2007;7(3):585-589
3 Edelman JL,Castro M.Quantitative image analysis of laser-induced choroidal neovascularization in rat.Exp Eye Res 2000;71(5):523-533
4 Zhang H,Liu ZL.Suppression of experimental choroidal neovaseularization utilizing anti-FLK1 monoclonal antibody.Int J Ophthalmol 2007;7(4):891-894
5 Xu JF,Wang YS.Review of glucocorticoid and diseases with choroidal neovascularization.Int J Ophthalmol 2007;7(3):772-775
6 何花,张红,赵春明,等.激光诱导的实验性脉络膜新生血管模型的定量研究.眼科研究2007;25(1):18-22
7 D' Amato R,Wesolowski E,Smith LE.Microscopic visualization of the retina by angiography with high-molecular-weitht gluorescein-labeled dextrans in the mouse.Microvasc Res 1993;46(2):135-142
8 杨秀梅,王雨生,徐建峰,等.激光诱导有色大鼠脉络膜新生血管的形态学观察.眼科新进展2006;27(3):161-166
1 王雨生,主编.脉络膜新生血管性疾病[M].北京:人民卫生出版社,2007.8-9.
2 唐由之,李学晶,王影.凉血化瘀中药治疗中心性渗出性脉络膜视网膜病变临床观察[J].中医杂志,2007;48(12):1099.
3 王晓庆,梁中琴,等.槲皮素抑制血管生成作用的实验研究[J].中国药理学通报,2004.20(10):1161-4.
4 Thaloor D.Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curvumin[J].Cell Growth Differ,1998,9(4):305.
5 李景恒,黄萍,詹宇坚,等.三七和丹参对视网膜新生血管化小鼠血管内皮细胞生长因子的影响[J].中国临床康复,2005,9(30):96-97.
6 李景恒,黄萍,彭耀崧.三七和丹参对视网膜新生血管化小鼠ICAM-1表达的影响 [J].中华现代眼科学杂志,2005,2(6):522-523.
7 高冬,宋军,胡娟,等.活血化瘀中药对鸡胚绒毛尿囊膜血管生成的影响.中国中西医结合杂志,2005,25(10):912-915.
1 徐建锋,王雨生,杨秀梅,等.地塞米松-聚乳酸-羟基乙酸纳米粒玻璃体内注射对激光诱导的大鼠脉络膜新生血管的抑制作用.中华眼底病杂志2007;23(1):33-37
2 CJulia TA,Criswell MH,Danis RP,et al.Choroidal veovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants.Br J 0phthalmol2003;87:1032-1037
3 Mandal S,Garg S,Venkatesh P,et al.Intravitreal Bevacizumab for Subfoveal Idiopathic Choroidal Neovascularization.Arch Ophthalmol.2007;125(11):1487-1492
4 Krzystolik MG,Afshari MA,Adamis AP,et al.Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.Arch Ophthal -mol2002;120(3):338-346
5 Olson JL,Courtney RJ,Mandava N.Intravitreal Infliximab and Choroidal Neovascularization in an Animal Model.Arch Ophthalmol 2007;125(9):1221-1224
6 Zhang H,Liu ZL.Suppression of experimental choroidal neovaseularization utilizing anti-FLK1 monoclonal antibody.Int J Ophthalmol 2007;7(4):891-894
7 王晓庆,梁中琴,等.槲皮素抑制血管生成作用的实验研究.中国药理学通报2004,20(10):1161-4
8 Thaloor D.Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curvumin[J].Cell Growth Differ,1998,9(4):305.
9 李景恒,黄萍,詹宇坚,等.三七和丹参对视网膜新生血管化小鼠血管内皮细胞生长因子的影响.中国临床康复2005,9(30):96-97
10 李景恒,黄萍,彭耀崧.三七和丹参对视网膜新生血管化小鼠ICAM-1表达的影响.中 华现代眼科学杂志2005,2(6):522-523
11 何花,张虹,赵春明,等.激光诱导的实验性脉络膜新生血管模型的定量研究.眼科研究2007;25(1):18-21
12 CiullaTA,Criswell MH,Danis RP,et al.Intravitreal Triamcinolone Acetonide Inhibits Choroidal Neovascularizationin a Laser-Treated Rat Model.Arch Ophthalmol.2001;119:399-404
13 兰兰,徐建锋,王雨生.糖皮质激素抑制脉络膜新生血管的信号通道.眼科新进展2007;27(12):940-944
14 高冬,宋军,胡娟,等.活血化瘀中药对鸡胚绒毛尿囊膜血管生成的影响.中国中西医结合杂志2005:25(10):912-915
1 Campochiaro PA,Soloway P,Ryan SJ,et al.The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration.Mol Vis 1999;5(11):34-38
2 Hartnett M E,Lappas A,Darland D,et al.Retinal pigment epithelium and endothelial cell interaction causes retinal pigment epithelial barrier dysfunction via a soluble VEGF dependent mechanism.Exp Eye Res 2003;77(5):593-599
3 Tatar O,Adam A,Shinoda K,et al.Matrix metalloproteinases in human choroidal neovascular membranes excised following verteporfin photodynamic therapy.Br J Ophthalmol 2007;91(3):1183-1189
4 曾军,姜德咏,刘湘平,等.MMP-2和MMP-9在脉络膜新生血管膜的表达.眼科新进展2004;24(6):455-457
5 Kvanta A,Shen WY,Sarman S,et al.Matrix metalloproteinase(MMP)expression in experimental choroidal neovascularization.Cur Eye Res 2000;21(3):684-690
6 张士胜,王康孙,王玲,等.MMP-9及TIMP-3在小鼠脉络膜新生血管形成中的作用.上海第二医科大学学报2003,23(3):206-209
7 Harkness KA,Adamson P,Sussman JD,et al.Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium.Brain 2000;123(Pt4):698-709
8 Bradey ME,Cheng LY,Bartsch DU,et al.Preventive versus treatment effect of Ag3340,a potent matrix metalloproteinase inhibitor in a rat model of choroidal neovascularization.J Ocul Pharmacol Ther 2004;20(3):217-237
9 Lambert V.Wielockx B,Munaut C.,et al.MMP-2 and MMP-9 synergize in promoting ehoroidal neovaseularization.FASEB J 2003;17(1):2290-2292
10 Murata T,Cui J,Taba KE.et al.The possibility of gene therapy for the treatment of choroidal neovascularization.0phthalmology2000,107(7):1364-1373